Rosalind Advisors portfolio
Concentrated managerType not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Rosalind Advisors reported a $266M portfolio of 29 positions to the SEC as of the end of Q2 2026. Its largest positions are DCTH, FENC, XERS. During the quarter it opened Abivax and exited CG Oncology and Viridian Therapeutics.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Rosalind Advisors has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Oct 13, 2026 · filed Oct 19, 2026 · filing ↗
Stake reported in the company · event of Aug 10, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jul 31, 2026 · filed Aug 12, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 12, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 12, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 12, 2026 · filing ↗
What changed this quarter
26 positions with a change (3 new, 7 added to, 10 trimmed, 6 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Verastem+86%more sharesIncreased4.6% → 5.7%
- CG Oncology−2.5 ppof portfolioSold out2.8% → —
- Vaxcyte−31%fewer sharesReduced6.9% → 4.4%
- Viridian Therapeutics−1.8 ppof portfolioSold out2.0% → —
- Celldex Therapeutics−39%fewer sharesReduced4.3% → 2.8%
- Fennec Pharmaceuticals+9.6%more sharesIncreased7.3% → 12.9%
- Cybin+28%more sharesIncreased3.0% → 4.9%
- Abivax+1.0 ppof portfolioNew— → 1.0%
- Xeris Biopharma Holdings−10.0%fewer sharesReduced7.7% → 8.7%
- Definium Therapeutics−0.9 ppof portfolioSold out1.0% → —
- Biocryst Pharmaceuticals−22%fewer sharesReduced3.6% → 2.7%
- Talphera+54%more sharesIncreased1.0% → 2.0%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Delcath SystemsDCTH15.6%
- Fennec PharmaceuticalsFENC12.9%
- Xeris Biopharma HoldingsXERS8.7%
- SavaraSVRA7.4%
- VerastemVSTM5.7%
- X4 PharmaceuticalsXFOR5.6%
- EyePointEYPT5.3%
- CybinHELP4.9%
- Vor BiopharmaVOR4.5%
- VaxcytePCVX4.4%
- MediwoundMDWD4.1%
- Celldex TherapeuticsCLDX2.8%
- Biocryst PharmaceuticalsBCRX2.7%
- Profound MedicalPROF2.1%
- TalpheraTLPH2.0%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 29
Q2 2026: 75%
Q2 2026: 11.2%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q4 2024 ↗filed Feb 11, 2025Amendment of Feb 14, 2025 (replaces the original) ↗
Declared options (6)
Besides stocks, Rosalind Advisors declared 4 puts (they gain if the stock falls) and 2 calls (they gain if it rises) with a notional of $3.0M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTSELLAS Life Sciences GroupSLSnew this quarter$2.3M
- CALLCG OncologyCGONnew this quarter$375K
- CALLEyePointEYPTnew this quarter$131K
- PUTIshares U.s. Aerospace &defense ETFnew this quarter$110K
- PUTSPDR Series Trustnew this quarter$35.2K
- PUTTenax TherapeuticsTENXnew this quarter$14.0K
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified. It meets the portfolio criteria of a concentrated manager, but its type is not verified: we found no official document that is enough to say what kind of entity it is. It may be an investment firm, but also an adviser adding up client accounts, a bank or a family vehicle. It counts in the tallies like the rest; keep that in mind when reading it. How the type is assigned
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Dalal StreetInvestment firm · $327M
- MuhlenkampInvestment firm · $345M
- Matthew 25 ManagementInvestment firm · $345M
- RR Advisors$346M
- Weybosset Research & Management$347M
- Stonehill Capital ManagementInvestment firm · $350M